These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32623477)

  • 1. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
    Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
    Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
    Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
    Front Immunol; 2018; 9():1798. PubMed ID: 30123221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-immunizing with PD-L1 induces CD8
    Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
    Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma.
    Nguyen-Pham TN; Jung SH; Vo MC; Thanh-Tran HT; Lee YK; Lee HJ; Choi NR; Hoang MD; Kim HJ; Lee JJ
    J Immunother; 2015 Oct; 38(8):330-9. PubMed ID: 26325377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
    Costa F; Das R; Kini Bailur J; Dhodapkar K; Dhodapkar MV
    Front Immunol; 2018; 9():2204. PubMed ID: 30319648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.
    Rosenblatt J; Glotzbecker B; Mills H; Vasir B; Tzachanis D; Levine JD; Joyce RM; Wellenstein K; Keefe W; Schickler M; Rotem-Yehudar R; Kufe D; Avigan D
    J Immunother; 2011 Jun; 34(5):409-18. PubMed ID: 21577144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
    Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
    Front Immunol; 2021; 12():737076. PubMed ID: 34659228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
    Kearl TJ; Jing W; Gershan JA; Johnson BD
    J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
    Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
    J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
    Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
    J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells.
    Choi SY; Kim Y; Lim B; Wee CB; Chang IH; Kim CS
    Investig Clin Urol; 2024 May; 65(3):300-310. PubMed ID: 38714521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
    Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
    Front Immunol; 2019; 10():1939. PubMed ID: 31475002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.
    Vo MC; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Rhee JH; Lee JJ
    Front Immunol; 2018; 9():1370. PubMed ID: 29967612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
    He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
    Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
    De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
    Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.